Literature DB >> 24810644

Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with non-muscle invasive bladder cancer? An update and cumulative meta-analysis.

Jiangang Pan1, Mo Liu, Xing Zhou.   

Abstract

Approximately 70% of newly diagnosed bladder tumors are non-muscle invasive bladder cancer (NMIBC). NMIBC accounts for approximately 80% of total bladder cancer cases. Bacillus Calmette-Guérin (BCG) instillation and maintenance is considered as the standard adjuvant treatment for superficial bladder cancer. A number of randomized studies have focused on the benefit of maintenance therapy following initial BCG induction. To provide further insights into the effect of intravesical instillation on recurrence in patients with NMIBC, we analyzed this relationship by conducting an updated detailed meta-analysis. Evidence suggested that adjuvant intravesical BCG with maintenance treatment is significantly effective for the prophylaxis of tumor recurrence in patients with NMIBC.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24810644     DOI： 10.1007/s11684-014-0328-0

Source DB:  PubMed          Journal:  Front Med        ISSN： 2095-0217            Impact factor:   4.592


  41 in total

1.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.

Authors:  Andreas Böhle
Journal:  Int Braz J Urol       Date:  2002 Nov-Dec       Impact factor: 1.541

2.  Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer.

Authors:  Shiro Hinotsu; Hideyuki Akaza; Seiji Naito; Seiichiro Ozono; Yoshiteru Sumiyoshi; Sumio Noguchi; Akito Yamaguchi; Satoshi Nagamori; Akito Terai; Yasutomo Nasu; Haruki Kume; Yoshihiko Tomita; Yoshinori Tanaka; Shoji Samma; Hirotsugu Uemura; Hirofumi Koga; Tomoyasu Tsushima
Journal:  BJU Int       Date:  2010-12-22       Impact factor: 5.588

3.  5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group.

Authors:  P U Malmström; H Wijkström; C Lundholm; K Wester; C Busch; B J Norlén
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

4.  Clinical experience with BCG alone versus BCG plus epirubicin.

Authors:  C Y Bilen; H Ozen; F T Aki; C Aygün; S Ekici; S Kendi
Journal:  Int J Urol       Date:  2000-06       Impact factor: 3.369

5.  Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.

Authors:  Martin G Friedrich; Uwe Pichlmeier; Hartwig Schwaibold; Stefan Conrad; Hartwig Huland
Journal:  Eur Urol       Date:  2007-03-12       Impact factor: 20.096

6.  Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea.

Authors:  In-Chang Cho; Eun Kyoung Kim; Jae Young Joung; Ho Kyung Seo; Jinsoo Chung; Weon Seo Park; Kang Hyun Lee
Journal:  Anticancer Res       Date:  2012-04       Impact factor: 2.480

7.  A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.

Authors:  Antonio Ojea; José Luís Nogueira; Eduardo Solsona; Nicolás Flores; Jesús María Fernández Gómez; Jesús Rodríguez Molina; Venancio Chantada; José Emilio Camacho; Luís Martínez Piñeiro; Rafael Hernandez Rodríguez; Santiago Isorna; Miguel Blas; José A Martínez-Piñeiro; Rosario Madero
Journal:  Eur Urol       Date:  2007-04-27       Impact factor: 20.096

8.  Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.

Authors:  Riikka Järvinen; Eero Kaasinen; Anna Sankila; Erkki Rintala
Journal:  Eur Urol       Date:  2009-04-16       Impact factor: 20.096

9.  Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.

Authors:  Tommaso Cai; Gabriella Nesi; Galliano Tinacci; Enzo Zini; Nicola Mondaini; Vieri Boddi; Sandra Mazzoli; Riccardo Bartoletti
Journal:  J Urol       Date:  2008-05-15       Impact factor: 7.450

10.  The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasive bladder cancer: a prospective randomized study.

Authors:  Ömer Gülpinar; Ahmet H Halilioglu; Mehmet Ilker Gökçe; Çagatay Göğüş; Sümer Baltaci
Journal:  Int Braz J Urol       Date:  2012 Jul-Aug       Impact factor: 1.541
View more
  5 in total

1.  A rare case of synchronous bilateral epididymal and testicular metastases of urothelial carcinoma of the bladder after intravesical bacillus Calmette-Guérin.

Authors:  Naotaka Nishiyama; Yoshinori Ikehata; Noriko Okuno; Masakiyo Sasahara; Ippei Sakamaki; Yoshihiro Yamamoto; Hiroshi Kitamura
Journal:  Int Cancer Conf J       Date:  2020-09-30

2.  Severe Respiratory Failure Due to Pulmonary BCGosis in a Patient Treated for Superficial Bladder Cancer.

Authors:  Katarzyna Lewandowska; Anna Lewandowska; Inga Baranska; Magdalena Klatt; Ewa Augustynowicz-Kopec; Witold Tomkowski; Monika Szturmowicz
Journal:  Diagnostics (Basel)       Date:  2022-04-07

3.  Prognostic factors of non-muscle invasive bladder cancer: a study based on next-generation sequencing.

Authors:  Yanxiang Shao; Xu Hu; Zhen Yang; Thongher Lia; Weixiao Yang; Kan Wu; Shangqing Ren; Sanchao Xiong; Weichao Dou; Shuyang Feng; Yaohui Wang; Yang Liu; Kang Wu; Xiang Li
Journal:  Cancer Cell Int       Date:  2021-01-06       Impact factor: 5.722

4.  Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette-Guerin: A single center experience and analysis of prognostic factors.

Authors:  Shouki N Bazarbashi; Haya J Azouz; Amal H Abu Sabaa; Ali H Aljubran; Ahmad M Alzahrani; Mohammed F Alotaibi
Journal:  Urol Ann       Date:  2016 Jul-Sep

5.  Do we have all the facts to determine the impact of bacillus Calmette-Guérin therapy on bladder cancer?

Authors:  Ratha Mahendran
Journal:  Transl Androl Urol       Date:  2018-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.